ArticleFrontiers in pharmacology2025
An analysis of the clinical application of paliperidone palmitate injection based on real-world.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the clinical application, adherence and relapse of paliperidone palmitate (PP) injection. Method: The information of patients treated with PP 1-month (PP1M), patients switching from PP1M to paliperidone palmitate 3-month (PP3M), and the relapse of patients after discharge from 1 January 2021 to 31 December 2023 was retrieved from the electronic medical record system. Descriptive statistics, two-tailed Results: 189 patients were administered with PP1M in this study accounted for 0.88% of all inpatients. 5 (9.09%) patients were switched from risperidone long-acting injection (RLAI) to PP1M. 45 (∼23.81%) patients were switched into PP3M. The patients without relapses were twice than relapsed patients after discharge of 1 year. Patients with initial episodes administered with PP1M showed fewer relapses than patients with non-initial episodes (11.11% vs. 34.72%; Conclusion: The current utilization of PP1M and conversion from PP1M to PP3M is low. Patients with initial episodes with and adhering to PP injection were at lower risk of relapse. Thus, the patients' adherence and the education about PP injections should be improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.